-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
2025-08-19
Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Receives Approval for Moroxydine API
On August 19, the morpholine nitrazole active pharmaceutical ingredient developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an API for use in marketed dosage forms. This marks the ninth new API product approved for Guangxiang Pharmaceutical so far this year.
2025-08-07
Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Receives Approval for Drotaverine Hydrochloride
On August 6, the active pharmaceutical ingredient of drotaverine hydrochloride developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an API for use in marketed dosage forms.
2025-04-23
“Innovative ‘API + Formulation’ Approach Yields Substantial Results! Shijiazhuang Sihua Pharmaceutical Group Receives Concurrent Approval for Two APIs—Dihydroxypropylxanthine and Acipimox”
Continuous innovation and steady accumulation ultimately lead to breakthroughs. On April 22, following the approval of three new products—dapagliflozin/metformin extended-release tablets (I) and arginine ibuprofen granules (0.2 g/0.4 g)—Shijiazhuang Sihua Pharmaceutical Group saw its subsidiary, Hebei Guangxiang Pharmaceutical Co., Ltd., successfully take over the baton: two active pharmaceutical ingredients—dihydroxypropylxanthine and acipimox—developed and submitted for approval were also approved on the same day, marking another significant achievement in the company’s pursuit of integrated “API-plus-formulation” development.
Felodipine API Approved by Shijiazhuang Sihua Pharmaceutical Group
Recently, the felodipine API developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has received national approval and been registered as an API for use in marketed dosage forms.
10
2025/04
Nimodipine API Approved by Shijiazhuang Sihua Pharmaceutical Group
On March 19, the nimodipine active pharmaceutical ingredient developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved for registration by the National Medical Products Administration and officially listed as an API used in marketed dosage forms. This marks another “dihydropyridine” class antihypertensive API to receive approval, following the 2025 approvals for benidipine hydrochloride and nicardipine hydrochloride APIs.
19
2025/03
The 70th! Shijiazhuang Sihua Pharmaceutical Group’s Nicardipine Hydrochloride API Has Been Approved
On March 5, the nicardipine hydrochloride API developed by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved for registration by the National Medical Products Administration and officially listed as an API used in marketed dosage forms. With this approval, the Group now boasts a portfolio of 70 bulk and specialty APIs, including 39 under Guangxiang Pharmaceutical, gradually establishing a robust API product matrix.
05
2025/03
On February 28, the Cangzhou Lingang Economic and Technological Development Zone held a mobilization conference and summary-and-award ceremony for high-quality development in 2025, at which enterprises that have made outstanding contributions to the zone’s high-quality development were solemnly commended. Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group was awarded the title of “Leading Enterprise in Scientific and Technological Innovation.”
28
2025/02
Recently, three technological advancement and industrialization projects of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, were selected as major science and technology special projects and science and technology program projects by Cangzhou City, which will further accelerate the company’s technological upgrading and product innovation, and provide policy support for the ongoing drive to elevate products toward high-end, branded, and green development.
15
2025/01
On January 10, the Data and Government Services Bureau of Huanghua City in the Bohai New Area of Cangzhou Municipality released the 2024 List of Model Integrity Cases, further highlighting exemplary models of integrity, leveraging their demonstration and leading role, and promoting a culture of honesty and trustworthiness. Shijiazhuang Sihua Pharmaceutical Group Hebei Guangxiang Pharmaceutical Co., Ltd. was recognized as an “Integrity Unit,” and Cui Yongbin was awarded the title of “Model Integrity Figure.”
12
2025/01
At the start of the new year, on January 6, the benidipine hydrochloride API submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved to be upgraded to “A,” making it the group’s first newly approved API variety in 2025.
07
2025/01
On December 30, Nicethamide, developed by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an active pharmaceutical ingredient for use in marketed dosage forms. To date, the Group has a total of 67 API products.
02
2025/01
Recently, Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group passed the provincial Level-2 standardization assessment for work safety, marking a new milestone in the company’s efforts to standardize work safety practices.
19
2024/12
On December 16, the Hebei Provincial Department of Industry and Information Technology released the list of 2024 Provincial Industrial Internet Benchmark Cases, with two projects from Shijiazhuang Sihua Pharmaceutical—“Development of a Manufacturing Execution System for Sterile Preparations” and “Construction Project of a Hyper-Converged Server Cloud Platform” submitted by Hebei Guangxiang Pharmaceutical Co., Ltd.—successfully selected.
17
2024/12
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
Business License
